ArticleBMC medical genomics2026
Clinical significance and impact on the cell behaviors of miR-758-5p/MMP-2 axis in ovarian cancer cells.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer (OC) is one of the most lethal gynecological malignant tumors globally.
objectivesThe objective of this research was to investigate the clinical significance and biological roles of the microRNA (miR)-758-5p/MMP-2 axis in OC. MATERIALS AND
methodsThis study recruited 150 epithelial ovarian cancer (EOC) patients. The Kaplan-Meier survival analysis examined the association between miR-758-5p levels and patient survival outcomes. Cox regression analysis identified critical factors influencing patient mortality risk. RT-qPCR quantified the expression of miR-758-5p and matrix metalloproteinase-2 (MMP-2). Cell proliferation was assessed by the CCK-8 assay, while cell migration and invasion were evaluated by the Transwell assay. Flow cytometry was utilized to measure the cell’s apoptosis rate. The dual-luciferase reporter assay confirmed the targeted regulatory relationship.
resultsMiR-758-5p was reduced in EOC patients (P < 0.0001). The expression of miR-758-5p (HR = 0.272, 95%CI = 0.131–0.561, P < 0.001), lymph node metastasis (HR = 1.951, 95%CI = 1.085–3.506, P = 0.026), and tumor stage (HR = 2.125, 95%CI = 1.108–4.078, P = 0.023) were critical factors influencing patient mortality risk. Specifically, high expression of miR-758-5p was significantly correlated with improved patient survival outcomes. Moreover, elevated levels of miR-758-5p effectively suppress the proliferation, migration, and invasion of OC cells while promoting apoptosis (P < 0.0001). The study further revealed that miR-758-5p directly negatively regulated MMP-2 expression. Overexpression of MMP-2 partially counteracted the effects of the miR-758-5p mimic on cell behavior (P < 0.0001).
conclusionThe miR-758-5p/MMP-2 axis may play a critical role in the OC progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.